Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 10/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | LITAF | Q99732 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137523 | 0.91 | SUV39H2 (0.44) | SUV39H2ALKPGK1GPR119TLR9 | |
| SCHEMBL16637088 | 0.83 | KIT (0.49) | SUV39H2ALKTLR9KCNH2 | |
| SCHEMBL25763287 | 0.80 | KCNH2 (0.48) | SUV39H2ALKGPR119TLR9MAPK8 | |
| SCHEMBL21137097 | 0.79 | ALK (0.44) | SUV39H2ALKPGK1GPR119TLR9 | |
| SCHEMBL16636900 | 0.79 | MAPK8 (0.39) | SUV39H2GPR119MAPK8KCNH2RET | |
| SCHEMBL18133895 | 0.78 | TLR9 (0.45) | SUV39H2ALKTLR9MAPK8KCNH2 | |
| SCHEMBL16636974 | 0.78 | MAPK8 (0.39) | SUV39H2GPR119MAPK8KCNH2RET | |
| SCHEMBL21137320 | 0.77 | KRAS (0.43) | SUV39H2ALKGPR119TNFLITAF | |
| SCHEMBL21099217 | 0.77 | KRAS (0.56) | ALKTNFLITAF | |
| SCHEMBL21136787 | 0.77 | KRAS (0.44) | SUV39H2ALKPGK1GPR119TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |